DNA single nucleotide variation (032)

The purpose of the scheme is to provide participating laboratories the opportunity to assess the quality of their genetic methods for analyzing the presence of specific variants in selected genes listed below:

Examinations
DNA–Apolipoprotein E (Apo E) genotype
DNA–Factor 2 (F2) g.20210G>A
DNA–Factor 5 (F5) c.1691G>A
DNA–Hemochromatosis (HFE) c.187C>G
DNA–Hemochromatosis (HFE) c.845G>A
DNA–Lactase gene (LCT) g.-13910C>T
DNA–Methylenetetrahydrofolate reductase (MTHFR) c.677C>T
DNA–Methylenetetrahydrofolate reductase (MTHFR) c.1298A>C

The scheme is aimed for clinical laboratories that perform genetic analysis of the presence of one or more of the above-mentioned components.

The sample material is blood or extracted DNA. Blank samples (water) are sometimes included.

Frequency: 2/year

Reports: Normally within two months from closing date.

Swedish laboratories register on our Swedish site. Laboratories from Denmark, Finland or Norway register through their national distributors, DEKS (Denmark), Aurevia (Finland) or Noklus (Norway). Laboratories from other countries register through Aurevia, our distributor outside Scandinavia. Please, note that the scheme may not be available in all countries.